Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186894 | 0.88 | LMNA (0.54) | LMNAHPGDMAPTCYP2C9CYP2C19 | |
| SCHEMBL81576 | 0.79 | LMNA (0.60) | LMNAHPGDMAPTCYP2C19SMN1; SMN2 | |
| SCHEMBL92994 | 0.76 | KDM4E (0.43) | SMN1; SMN2CCNB2CCNE2CDK1CCNB1 | |
| SCHEMBL12444294 | 0.76 | P4HTM (0.44) | LMNAHPGDP4HTMCCNB2CCNE2 | |
| SCHEMBL18532059 | 0.76 | KCNA5 (0.52) | LMNAHPGDMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL19625792 | 0.75 | MAPT (0.56) | LMNAHPGDP4HTMMAPTCYP2C9 | |
| SCHEMBL20228172 | 0.75 | LMNA (0.48) | LMNAHPGDMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL3424839 | 0.73 | ALDH1A1 (0.55) | LMNAHPGDP4HTMMAPTCYP2C9 | |
| SCHEMBL79942 | 0.73 | HPGD (0.56) | LMNAHPGDMAPTCYP2C9CYP2C19 | |
| SCHEMBL18233757 | 0.72 | PTPN1 (0.48) | LMNAHPGDP4HTMMAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-11267823-B2 | Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| EP-3187225-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3187225-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3372281-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3372281-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2021-07-07 | — | — | EP | disclosed |
| US-7858788-B2 | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | disclosed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | disclosed |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| CN-101346376-A | Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase | SHIONOGI & CO (JP) | 2009-01-14 | — | — | CN | disclosed |
| EP-1950212-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE | Shionogi Co., Ltd. (JP) | 2008-07-30 | — | — | EP | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852434-A1 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | Shionogi Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | NR4A1, HAT1, NR4A2 | LMNA 4549/4885HPGD 2498/4885P4HTM 1325/4885 |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, TYMS, POLA1 | LMNA 2002/4885HPGD 2031/4885P4HTM 1126/4885 |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | CDK20, CYP4A22, CDK10 | LMNA 969/4885HPGD 2604/4885P4HTM 2054/4885 |
| US-11267823-B2 | Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity | TYMP, TYMS, POLA1 | LMNA 1966/4885HPGD 2052/4885P4HTM 1176/4885 |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, CDKN1A, POLL | LMNA 2795/4885HPGD 2798/4885P4HTM 1198/4885 |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | NR4A1, NCOA4, NR4A2 | LMNA 4751/4885HPGD 4096/4885P4HTM 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.